Sustained and Subsequent Response to Atogepant Among Individuals With Episodic Migraine With Prior Treatment Failure: Post Hoc Analysis of the ELEVATE Trial

被引：0
|
作者：
Sacco, Simona [1 ]
Nagy, Krisztian [2 ]
Chalermpalanupap, Natty [3 ]
Vernieri, Fabrizio [4 ]
Smith, Jonathan H. [5 ]
Holle-Lee, Dagny [6 ]
Liu, Yingyi [5 ]
Carr, Karen [5 ]
Pozo-Rosich, Patricia [7 ,8 ]
Lipton, Richard B. [9 ]
机构：
[1] Univ LAquila, Laquila, Italy
[2] AbbVie, Budapest, Hungary
[3] AbbVie, Madison, NJ USA
[4] Univ Campus Biomed Roma, Rome, Italy
[5] AbbVie, N Chicago, IL USA
[6] Univ Essen Gesamthsch, West German Headache & Vertigo Ctr Essen, Dept Neurol, Essen, Germany
[7] Vall Hebron Univ Hosp, Barcelona, Spain
[8] Univ Autonoma Barcelona, Barcelona, Spain
[9] Albert Einstein Coll Med, Bronx, NY USA
来源：
CEPHALALGIA | 2023年 / 43卷 / 1supp期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IHC23-PO-2
引用
收藏
页码：265 / 266
页数：2
相关论文
共 50 条
  • [1] Sustained and Subsequent Response to Atogepant Among Individuals With Chronic Migraine: Post Hoc Analysis of the PROGRESS Trial
    Lipton, R.
    Chalermpalanupap, N.
    Nahas-Geiger, S.
    Pozo-Rosich, P.
    McAllister, P.
    Tatsuoka, Y.
    Liu, Y.
    Dabruzzo, B.
    Smith, J.
    Bilchik, T.
    [J]. HEADACHE, 2023, 63 : 168 - 169
  • [2] Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS
    Lipton, R. B.
    Chalermpalanupap, N.
    Tatsuoka, Y.
    Nagy, K.
    Liu, Y.
    Carr, K.
    McAllister, P.
    Nahas, S. J.
    Trugman, J. M.
    Sacco, S.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [3] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
    Pozo-Rosich, P.
    Nagy, K.
    Tassorelli, C.
    Lanteri-Minet, M.
    Sacco, S.
    Nezadal, T.
    Finnegan, M.
    Guo, H.
    Ferreira, De Abreu R.
    Trugman, J.
    [J]. HEADACHE, 2023, 63 : 117 - 117
  • [4] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
    Pozo-Rosich, Patricia
    Nagy, Krisztian
    Tassorelli, Cristina
    Lanteri-Minet, Michel
    Sacco, Sara
    Nezadal, Tomas
    Finnegan, Michelle
    Guo, Hua
    Ferreira, Rosa De Abreu
    Trugman, Joel M.
    [J]. CEPHALALGIA, 2023, 43 (1supp) : 47 - 49
  • [5] Atogepant for the Preventive Treatment of Migraine in Participants With Prior Treatment Failure: The ELEVATE Trial
    Pozo-Rosich, P.
    Nagy, K.
    Tassorelli, C.
    Lanteri-Minet, M.
    Sacco, S.
    Nezadal, T.
    Finnegan, M.
    Guo, H.
    Gandhi, P.
    Trugman, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 212 - 213
  • [6] Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial
    Dodick, D.
    Nahas, S.
    Pozo-Rosich, P.
    Bilchik, T.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B.
    Lipton, R.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [7] Subsequent response to atogepant in individuals with episodic migraine after an initial inadequate response: Post hoc analyses of a 12-week phase 3 trial
    Dodick, D. W.
    Nahas, S. J.
    Pozo-Rosich, P.
    Bilchik, T. R.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B. L.
    Lipton, R. B.
    [J]. HEADACHE, 2022, 62 : 164 - 165
  • [8] Impact of Atogepant on Migraine-Specific QoL Among Individuals With Episodic Migraine and Preventive Treatment Failure
    Tassorelli, C.
    Gandhi, P.
    Sacco, S.
    Pozo-Rosich, P.
    Lanteri-Minet, M.
    Nezadal, T.
    Trugman, J.
    Luo, L.
    Stokes, J.
    Nagy, K.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 214 - 215
  • [9] Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12-and 52-Week Phase 3 Trials
    Lipton, R.
    Nahas, S.
    Pozo-Rosich, P.
    Bilchik, T.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B.
    Dodick, D.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [10] Sustained response to atogepant in individuals with episodic migraine: Post hoc analyses of 12-and 52-week phase 3 trials
    Lipton, R. B.
    Nahas, S. J.
    Pozo-Rosich, P.
    Bilchik, T. R.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B. L.
    Dodick, D. W.
    [J]. HEADACHE, 2022, 62 : 165 - 166
12345